Stifel Maintains Hold Rating for Inogen: Here's What You Need To Know

Stifel has decided to maintain its Hold rating of Inogen INGN and lower its price target from $40.00 to $30.00.

Shares of Inogen are trading down 4.15% over the last 24 hours, at $23.91 per share.

A move to $30.00 would account for a 25.5% increase from the current share price.

About Inogen

Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. The majority of rental revenue comes from Medicare service reimbursement programs. Internationally, Inogen sells its products through distributors or large gas companies and home oxygen providers. Inogen generates the majority of its revenue in the United States.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.